Germs 101 (infographic)
After Treatment: A Hodgkin Lymphoma Survivor Talks about What Happens in Remission
In 2013, Josh Raub’s life was going according to plan. At 29 years old, he was working at his dream job as a professor and pharmacy specialist at an academic medical center in Detroit. He and his wife had just bought their first home and were talking about starting a family. “It was just this perfect future that we were planning for ourselves,” he says. Then he got sick.
After Treatment: A Hodgkin Lymphoma Survivor Talks about What Happens in Remission
In 2013, Josh Raub’s life was going according to plan. At 29 years old, he was working at his dream job as a professor and pharmacy specialist at an academic medical center in Detroit. He and his wife had just bought their first home and were talking about starting a family. “It was just this perfect future that we were planning for ourselves,” he says. Then he got sick.
September Social Media Round-Up—Prostate Cancer Awareness, TIME Executives of the Year, and More
As we enter fall, the days are getting shorter and the nights are getting cooler, but Pfizer’s social media channels are as active as ever.
September Social Media Round-Up—Prostate Cancer Awareness, TIME Executives of the Year, and More
As we enter fall, the days are getting shorter and the nights are getting cooler, but Pfizer’s social media channels are as active as ever.
Bourla at Concordia: The Business of Better Health
At the 2026 Concordia Annual Summit, Albert Bourla joined that conversation via a mainstage discussion with Alice Park, senior health correspondent at TIME, titled "The Business of Better Health."
Bourla at Concordia: The Business of Better Health
At the 2026 Concordia Annual Summit, Albert Bourla joined that conversation via a mainstage discussion with Alice Park, senior health correspondent at TIME, titled "The Business of Better Health."
How AI Is Helping Match Patients to Clinical Trials Faster
Before researchers can determine whether a potential new treatment is effective, they have to find enough eligible volunteers willing and able to participate in a trial. This process represents one of the biggest challenges in drug development.
How AI Is Helping Match Patients to Clinical Trials Faster
Before researchers can determine whether a potential new treatment is effective, they have to find enough eligible volunteers willing and able to participate in a trial. This process represents one of the biggest challenges in drug development.
Behind the Science: Reprogramming Resistance to Prostate Cancer Treatment
Prostate cancer is one of the most common – and most lethal – cancers in men. In the United States alone, nearly 300,000 new cases are diagnosed each year, and it remains the second-leading cause of cancer death among men.
Behind the Science: Reprogramming Resistance to Prostate Cancer Treatment
Prostate cancer is one of the most common – and most lethal – cancers in men. In the United States alone, nearly 300,000 new cases are diagnosed each year, and it remains the second-leading cause of cancer death among men.
After Treatment: A Hodgkin Lymphoma Survivor Talks about What Happens in Remission
In 2013, Josh Raub’s life was going according to plan. At 29 years old, he was working at his dream job as a professor and pharmacy specialist at an academic medical center in Detroit. He and his wife had just bought their first home and were talking about starting a family. “It was just this perfect future that we were planning for ourselves,” he says. Then he got sick.
After Treatment: A Hodgkin Lymphoma Survivor Talks about What Happens in Remission
In 2013, Josh Raub’s life was going according to plan. At 29 years old, he was working at his dream job as a professor and pharmacy specialist at an academic medical center in Detroit. He and his wife had just bought their first home and were talking about starting a family. “It was just this perfect future that we were planning for ourselves,” he says. Then he got sick.
September Social Media Round-Up—Prostate Cancer Awareness, TIME Executives of the Year, and More
As we enter fall, the days are getting shorter and the nights are getting cooler, but Pfizer’s social media channels are as active as ever.
September Social Media Round-Up—Prostate Cancer Awareness, TIME Executives of the Year, and More
As we enter fall, the days are getting shorter and the nights are getting cooler, but Pfizer’s social media channels are as active as ever.
Bourla at Concordia: The Business of Better Health
At the 2026 Concordia Annual Summit, Albert Bourla joined that conversation via a mainstage discussion with Alice Park, senior health correspondent at TIME, titled "The Business of Better Health."
Bourla at Concordia: The Business of Better Health
At the 2026 Concordia Annual Summit, Albert Bourla joined that conversation via a mainstage discussion with Alice Park, senior health correspondent at TIME, titled "The Business of Better Health."
How AI Is Helping Match Patients to Clinical Trials Faster
Before researchers can determine whether a potential new treatment is effective, they have to find enough eligible volunteers willing and able to participate in a trial. This process represents one of the biggest challenges in drug development.
How AI Is Helping Match Patients to Clinical Trials Faster
Before researchers can determine whether a potential new treatment is effective, they have to find enough eligible volunteers willing and able to participate in a trial. This process represents one of the biggest challenges in drug development.
Behind the Science: Reprogramming Resistance to Prostate Cancer Treatment
Prostate cancer is one of the most common – and most lethal – cancers in men. In the United States alone, nearly 300,000 new cases are diagnosed each year, and it remains the second-leading cause of cancer death among men.
Behind the Science: Reprogramming Resistance to Prostate Cancer Treatment
Prostate cancer is one of the most common – and most lethal – cancers in men. In the United States alone, nearly 300,000 new cases are diagnosed each year, and it remains the second-leading cause of cancer death among men.